Loading clinical trials...

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria

NCT06873516•Evommune, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
•Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
•Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.

Exclusion Criteria

•Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
•Use of certain medications.
•History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
•Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.

Locations (53)

Cahaba Dermatology Skin Health Center

Birmingham, Alabama, United States

Velocity Clinical Research, Mobile

Mobile, Alabama, United States

Center for Dermatology Clinical Research

Fremont, California, United States

Antelope Valley Clinical Trials

Lancaster, California, United States

Northridge Clinical Trials

Northridge, California, United States

NorthBay Clinical Research

Santa Rosa, California, United States

Integrated Research of Inland

Upland, California, United States

FOMAT Medical Research

Ventura, California, United States

AMR Fort Myers

Fort Myers, Florida, United States

Advanced Clinical Research Institute

Tampa, Florida, United States

Key Dates

Start Date

March 20, 2025

Primary Completion Date

May 1, 2026

Completion Date

May 1, 2026

Last Updated

January 21, 2026

Enrollment

160

ESTIMATED participants

Conditions

Chronic Spontaneous Urticaria

Interventions

EVO756

DRUG

EVO756

DRUG

EVO756

DRUG

Placebo control

DRUG

Contacts

Polina Bukshpun

CONTACT

+1-818-536-2358 polina.bukshpun@evommune.com

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405

Chronic Inducible UrticariaChronic Spontaneous Urticaria

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

NCT07230418

Chronic Spontaneous Urticaria

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Inclusion Criteria

Exclusion Criteria

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria